Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Apr 26, 2019* Praluent is the first PCSK9 inhibitor that has shown a meaningful reduction in death from any cause
-
Apr 10, 2019* Sanofi continues its commitment to helping reduce cost burden for people living with diabetes with first-ever insulin savings program
-
Mar 11, 2019* Only therapy that targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis
-
Feb 27, 2019* Soliqua 100/33 now approved as an add-on to diet and exercise for adults with type 2 diabetes
-
Feb 25, 2019Praluent® (alirocumab) continues to be available in the U.S.
-
Feb 11, 2019* This is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients
-
Feb 6, 2019- First medicine approved in the U.S. specifically for the treatment of aTTP, a rare blood-clotting disorder